Arstat Pharmaceuticals

Transforming Standard of Care for 60+ Million US Women with a De-Risked, Phase III-Ready Pipeline

Engaging Select Investors and Leadership Partners for an H1 2027 Nasdaq IPO

Contact:

Arkady Rubin, PhD, President/CSO
arubin@arstatinc.com
+1 347-385-0878
www.arstatinfo.com

August 10, 2026

The Arstat Opportunity: Executive Summary

Arstat is taking its Phase III pipeline public in H1 2027 at a conservative valuation, creating a massive value gap for early investors.

Blue-Chip Leadership: Track Record of Billion-Dollar Successes

Arkady Rubin, PhD, Founder, President/CSO

- **Co-inventor of Ortho Tri-Cyclen Lo®** ($1.8B/year in current market conditions)
- **Inventor of all 16 Arstat patents.**



Jon Stelzmiller, Acting CEO, Prospective Board Member

- Former President of US Lupin
- **Former SVP and GM at Bayer ($1B Women's Health Franchise**).

The Pipeline

Four first-in-class products, **two are ready for Phase III. Two are likely blockbusters.**

Banker Validation

Interest expressed by potential IPO underwriters; **two draft engagement letters already received.**

Zero debt, clean cap table, and exceptional capital efficiency

A De-Risked, Phase III-Ready Pipeline: Four First-to-Market Products Designed to Dominate Areas of High Unmet Need

Total Market: > 60 Million US Women **Projected US Sales: $4.78B (Upside)**

A Fortress of 16 Granted US and EU Patents (fully assigned to Arstat prior to the IPO)

Product	Indication	Status
NUVOCEPT™	**The first oral contraceptive** designed for **≈ 20 million women** with high BMI **Likely Blockbuster**	**Phase III-ready**
DUACEPT™	**The first oral contraceptive** designed for **≈ 3 million women** with cardio risk factors.	**Phase III-ready**
PREMRING™	**A first-in-category vaginal ring** for **≈ 14 million women** with uterine fibroids and endometriosis **Likely Blockbuster**	**Phase IIb Asset**
ENHANTA™	**A first-in-category non-hormonal therapy** for **>25 million women** with painful, heavy periods	**Phase IIb Asset**

Regulatory Advantage: All products are designed for the **505(b)(2) NDA pathway,** leveraging existing data for a much faster, lower-cost route to approval.

For the First Time, Addressing Urgent Public Health Priorities

The Problem:
20 million US women with high BMI need reliable birth control, with common choices performing poorly in this group

Our Solution:
NUVOCEPT
(combined oral contraceptive)

Impact: The first and only contraceptive designed explicitly for overweight and obese women (≈ 60% of the market)

The Problem:
13 million US women have had their uterus removed due to uterine fibroids and endometriosis

Our Solution:
PREMRING
(medicated vaginal ring)

Impact: Designed for comfortable long-term treatment significantly reducing the need for devastating radical surgeries

"Women will LOVE it." - Andrea S. Lukes, MD, MHSc, FACOG
(Conducted >150 trials of women's health products).

The Full Exit: *A Clear, Capital-Efficient 4-5 Year Path to a >$1.2B Market Cap*

Event: Bridge Financing ($1M)

Valuation: $10M

Event: IPO

Targeted Valuation*: $120-150M

Event: Complete Planned R&D

- NUVOCEPT & DUACEPT - FDA approval;
- ENHANTA nearing FDA approval
- PREMRING sold or Phase III

Projected Market Cap: $800-900M

Event: Exit (Product Out-Licensing or Company Sale)

OR

Projected Market Cap >$1.2B

**Pre-money valuation*

The Deal Math: $10M Entry → $120–150M IPO Target

Invest at **a $10M cap,** target an IPO of **$120-150M** (pre-money valuation)



Banker Validation

Interest expressed by several potential underwriters; two draft engagement letters received.

Arstat's IPO target is set at a conservative **15-20%** of its $815M risk-adjusted NPV (rNPV) and current peer valuations, leaving substantial room for **post-IPO upside.**

Conservative Portfolio Valuations Supporting the IPO Path



*NPV determined in collaboration with Bio-strategy Analytics using DCF and rNPV methods.
A 47-page report was prepared per the best industry standards (available).

Securing an H1 2027 Nasdaq Listing

Q3 2026 (Structuring)	Q4 2026 - Q1 2027 (Regulatory)	Q1-Q2 2027 (Marketing)	H1 2027 (Liquidity)
We are here			
• PCAOB Audit • Executed IPO Engagement Letter	• Draft S-1 • Confidential SEC Filing	• SEC Comment Resolution • Public S-1 Filing	• Roadshow • **Nasdaq IPO**

- We are selectively engaging the Listing CEO, Chairman of the Board, and IPO experts
- Attractive, IPO-aligned equity packages
- We are open to discussions with select strategic investor partners.

The IPO path is defined. The question is who will help shepherd it.